The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

【导读】血管完整性受损促进癌细胞外渗和转移。然而，结直肠癌（CRC）中导致血管完整性破坏的机制仍不清楚。1月21日，济宁医学院研究团队在期刊《Cell Death&Disease》上发表了研究论文，题为“PCDH17 induces ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

An accurate new blood test for colon cancer, the fourth leading cause of cancer deaths in the US, has been reported.

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for ...